Selection drivers for recently prescribed lasmiditan, ubrogepant, or rimegepant for the acute treatment of migraine: Results from an annual cross-sectional patient chart audit in the United States
被引:0
作者:
Schobel, V. R.
论文数: 0引用数: 0
h-index: 0
机构:
Spherix Global Insights, Exton, PA USASpherix Global Insights, Exton, PA USA